Seres Therapeutics(MCRB)

CAMBRIDGE, MABiotechnology2 H-1B visas (FY2023)

Focus: Seres Therapeutics is a public biotech company developing microbiome-derived therapeutics to treat infectious diseases and antibiotic-associated complications. The company is a pioneer in the live biotherapeutic drug space with a clinical-stage pipeline focused on C. difficile infection and inflammatory bowel disease.

Infectious Diseases

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Seres Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Seres Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$0K

Pipeline & Clinical Trials

SER-109

Clostridioides Difficile Infection

N/A

Clinical Trials (1)

NCT02437500Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI)

N/A

Help build intelligence for Seres Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneer in emerging microbiome therapeutic space with differentiated science and unmet clinical needs in infectious diseases
Advanced pipeline with SER-109 in Phase 3 for C. difficile infection, a significant commercial opportunity if successful
Public company status provides liquidity and potential equity upside; 2/2 H1B approvals in 2023 signals willingness to hire specialized talent

Watch Out For

Pre-revenue stage with significant cash burn: $113.7M net loss in FY2025, $250.2M in FY2024, with only $31M cash on hand—runway risk is acute
Zero active job postings and no hiring department breakdown indicates potential hiring freeze or organizational contraction
Early-stage pipeline with Phase 3 as the only advanced program; single-asset risk if SER-109 fails

Generated by Claude from Seres Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Placebo for antibiotic

Metastatic Melanoma

PHASE_1

Clinical Trials (1)

NCT03817125Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention

Phase 1

SER-287

Ulcerative Colitis

PHASE_1

Clinical Trials (1)

NCT02618187A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis

Phase 1

SER-262

Clostridium Difficile Infection

PHASE_1

Clinical Trials (1)

NCT02830542SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence

Phase 1

Vancomycin Pre-Treatment

Allogeneic Hematopoietic Stem Cell Transplantation

PHASE_1

Clinical Trials (1)

NCT04995653A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT

Phase 1

SER-109

Clostridium Difficile

PHASE_2

Clinical Trials (1)

NCT02437487SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)

Phase 2

Vancomycin Pre-Treatment

Ulcerative Colitis

PHASE_2

Clinical Trials (1)

NCT03759041A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis

Phase 2

SER-109

Clostridium Difficile Infection

PHASE_3

Clinical Trials (1)

NCT03183128ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection

Phase 3

SER-109

Clostridioides Difficile Infection

PHASE_3

Clinical Trials (1)

NCT03183141ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2013

Portfolio: 9 clinical trials

Top TAs: Immunology, Oncology

H-1B (2023): 2 approvals

Publications: 25 in PubMed

SEC Filings: 2 available

Therapeutic Area Focus

Immunology

2 pipeline

Oncology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

R&D Spend

$118M7%

Net Income

-$114M

Cash

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Integrating microbiomes into One Health: insights from the 2025 One Health World Microbiome Partnership Summit.

The Lancet. Microbe

2026

PMID:41525776

The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome.

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Seres Therapeutics(MCRB)

About Seres Therapeutics

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Seres Therapeutics(10)

Open Jobs (0)

Financials (FY2025)

Visa Sponsorship

Research Publications(10)